Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00430690
Other study ID # IRB00002489
Secondary ID R01DA018294-01A2
Status Completed
Phase
First received
Last updated
Start date September 2006
Est. completion date July 19, 2011

Study information

Verified date August 2019
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Chronic cocaine administration leads to changes in brain function that persist long after the acute withdrawal phase. The acoustic startle response (ASR) is a well characterized reflexive response to a sudden acoustic stimulus. The ASR is mediated by a simple 3-synapse subcortical circuit; it is modulated in part by brain areas and neurotransmitters associated with cocaine administration. Our initial study and subsequent replication reveals a profound diminution of the ASR in cocaine-dependent subjects after a brief period of abstinence. Our preliminary findings indicate that first degree relatives of cocaine-dependent subjects also have reduced startle compared to healthy controls. The findings of low ASR in rats and humans during cocaine washout and low ASR in family members suggests there may be both a trait and state component of the startle reductions we have reported.

The central objectives of this proposal are to dissect this finding with regard to its development and persistence in early and later phases of cocaine abstinence in humans; to ascertain whether startle reduction and its potential normalization during later abstinence is a predictor of clinical course in human subjects with cocaine dependence; and to examine whether startle reduction is, at least in part, a vulnerability trait for the development of cocaine dependence. This latter Aim will be carried out in humans by testing siblings of cocaine-dependent subjects.

Cocaine dependence is an enormous public health problem. The significance of this work lies in the potential for the ASR reduction to serve as a reliable, easily repeatable biological measure of cocaine-induced brain changes that may enhance outcome prediction so that tailored treatments may be directed at those patients most vulnerable to relapse, given the restriction of resources for available for substance abuse treatment.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date July 19, 2011
Est. primary completion date July 19, 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

Cocaine dependent subjects:

1. males or females,

2. age 18-80,

3. with a DSM-IV diagnosis of cocaine dependence,

4. a usage history characterized by a minimum of 1 year of at least $50 per day or weekly binges of at least $200 of cocaine use.

Exclusion Criteria:

1. current clinically significant medical illness (including HIV, because of possible confound of neurological involvement),

2. current or past neurological illness, and no history of head trauma with loss of consciousness = 5 minutes because of the possible confound of neurological damage to startle-modulating brain areas,

3. other Axis I psychiatric disorder currently or in the previous three months with the exception of substance induced disorders as determined by SCID,

4. history of schizophrenia, schizoaffective disorder, posttraumatic stress disorder, or bipolar disorder,

5. known hearing impairments (intact hearing will be insured by brief audiology screening),

6. dependence on other drugs or alcohol within the previous 6 months, as confirmed by ASI.

Healthy controls:

1. males or females,

2. age 18-80.

Exclusion criteria:

1. history of any Axis I psychiatric illness or history of treatment as determined by SCID Axis I,

2. substance dependence or abuse history by ASI and SCID,

3. no current clinically significant medical illness (including HIV),

4. current or past neurological illness, or history of head trauma with loss of consciousness = 5 minutes because of the possible confound of neurological damage to startle-modulating brain areas,

5. known hearing impairments (intact hearing will be insured by brief audiology screening),

6. Axis I disorder, including substance dependence, in first degree family member.

Family members of cocaine subjects:

1. males or females,

2. age 18-80,

3. family member of cocaine-dependent subject enrolled in study.

Exclusion criteria:

1. history of any Axis I psychiatric illness or history of treatment as determined by SCID Axis I,

2. substance dependence history by ASI and SCID, or substance abuse within the prior 5 years,

3. no current clinically significant medical illness (including HIV),

4. current or past neurological illness, or history of head trauma with loss of consciousness,

5. known hearing impairments

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
acoustic startle testing
acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes

Locations

Country Name City State
United States Atlanta Veterans Adminstration Medical Center Decatur Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acoustic startle magnitude Magnitude of acoustic startle response as measured by electromyography of eyeblink. at baseline
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1